Aspire Biopharma Hldgs Inc.
13F holders, Q1 2026 (March 31)2holders −28
0new positions
25sold out
$0.33avg. 13F price*
At the end of Q1 2026, 2 institutions reported holding Aspire Biopharma Hldgs Inc. in their 13F filings, down 28 from Q4 2025. 0 opened new positions and 25 sold out. The largest holders were Crossingbridge Advisors, LLC ($7K) and Valley Wealth Managers, Inc. ($1K).
- Company
- Aspire Biopharma Hldgs Inc.
- CUSIP
- 738920107
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 25 | $802K |
All 13F filers, Q4 2025 → Q1 2026: 6,117,538 shares sold, net −6,117,538 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Crossingbridge Advisors, LLC | 0.00% | No change | 24,348 | $7K |
| Valley Wealth Managers, Inc. | 0.00% | Reduce -97.5% | 1,000 | $1K |
"% of holder's portfolio" is ASPIRE BIOPHARMA HLDGS INC's weight in each manager's 13F, not the share of Aspire Biopharma Hldgs Inc. the manager owns.